Log in to search using one of your social media accounts:


Axovant ’s Phase III trial of Alzheimer's disease drug fails to meet primary endpoints

Axovant Sciences has reported negative top-line results from its Phase III MINDSET clinical trial of intepirdine conducted to treat mild-to-moderate Alzheimer's disease (AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

You're reading 7 Reasons To Meditate, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles. Do you always feel tired, stressed, and angry? Are you impulsive and can`t seem to stop snapping at people for the wrong reasons? If you say Yes, then you have to meditate more often. Why You Must Meditate Meditation is one of the best physical and spiritual activities you can gift yourself. For just 10 minutes each day, you can improve your mood, boost your energy and increase tranquility. But it`s not just about that. Researchers have ...
Source: PickTheBrain | Motivation and Self Improvement - Category: Consumer Health News Authors: Tags: featured health and fitness psychology self improvement alzheimer's health benefits of meditation meditate pickthebrain sleep aid Source Type: blogs
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Review Source Type: research
This article is part of the Special Issue “Vascular Dementia”. We propose that hyperhomocysteinemia (HHcy) results in a pro‐inflammatory response at the vasculature, which activates the matrix metalloproteinase MMP9. MMP9 subsequently cleaves the a‐b dystroglycan complex, leading to disruption of the astrocytic connection with the vasculature. MMP9 also degrades the dystrophin Dp71 anchoring complex, resulting in the down‐regulation of astrocytic end‐foot channels. The end result of the end‐foot disruption is impaired potassium homeostasis in the brain and impaired neurovascular coupling.
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Review Source Type: research
DEMENTIA is an umbrella term for a collection of symptoms that result from damage to the brain caused by different diseases - for example Alzheimer ’s. There is currently no cure available, but expert believe there are ways of reducing the risk of it developing.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
In conclusion, death is a natural part of human existence, but human progress is essentially a story of overcoming undesirable natural limits. In the near future, technological progress might make it possible to stop natural biological death. Should humankind embrace such technology? Yes: Even though such technology would not be without risks, the risks are almost certainly manageable. The benefits of ending natural death, on the other hand, are immense. Death is an obstacle that is slowing down human progress. If we remove that obstacle, humankind could increase the speed of both its moral and its epistemic progress. ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Di Guardo G PMID: 29348035 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
CONCLUSIONS AND RELEVANCE: Clinical studies of AD are likely biased toward participants who are more liberal and have higher confidence in science than the general population. This recruitment bias may be reduced by lowering the trust demanded of participants through measures such as returning research results to participants. PMID: 29351092 [PubMed - as supplied by publisher]
Source: Alzheimer Disease and Associated Disorders - Category: Psychiatry Tags: Alzheimer Dis Assoc Disord Source Type: research
Authors: Milán-Tomás Á, Shapiro CM Abstract The purpose of this review is to provide an overview of the research regarding circadian rhythms in Alzheimer disease (AD). Furthermore, this paper explores the role of melatonin in the pathogenesis of AD and the limitation of trials addressing circadian rhythms disturbances in the AD population. A literature search using Medline with PubMed and Embase was carried out identifying papers focusing on circadian rhythms in AD. Sleep disorders and especially circadian rhythm disturbances are very common in the elderly population but definitely more pronoun...
Source: Alzheimer Disease and Associated Disorders - Category: Psychiatry Tags: Alzheimer Dis Assoc Disord Source Type: research
Association between the APOE ε4 Allele and Late-Onset Alzheimer's Disease in an Ecuadorian Mestizo Population. Int J Alzheimers Dis. 2017;2017:1059678 Authors: Montufar S, Calero C, Vinueza R, Correa P, Carrera-Gonzalez A, Villegas F, Moreta G, Paredes R Abstract Alzheimer's disease (AD) is the most common neurodegenerative disease. It has two main pathological hallmarks: amyloid plaques and neurofibrillary tangles. The APOE ε4 allele has been recognized as the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD) in several populations worldwide, yet the risk varies b...
Source: International Journal of Alzheimers Disease - Category: Geriatrics Tags: Int J Alzheimers Dis Source Type: research
Authors: Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK Abstract In recent years, the incidental rate of neurodegenerative disorders has increased proportionately with the aging population. Alzheimer's disease (AD) is one of the most commonly reported neurodegenerative disorders, and it is estimated to increase by roughly 30% among the aged population. In spite of screening numerous drug candidates against various molecular targets of AD, only a few candidates - such as acetylcholinesterase inhibitors are currently utilized as an effective clinical therapy. However, targeted drug delivery of these drugs to the...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
More News: Alzheimer's | Clinical Trials | Pharmaceuticals